- /
- Supported exchanges
- / US
- / JANX.NASDAQ
Janux Therapeutics Inc (JANX NASDAQ) stock market data APIs
Janux Therapeutics Inc Financial Data Overview
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Janux Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Janux Therapeutics Inc data using free add-ons & libraries
Get Janux Therapeutics Inc Fundamental Data
Janux Therapeutics Inc Fundamental data includes:
- Net Revenue: 439 K
- EBITDA: -142 796 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.4612
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Janux Therapeutics Inc News
New
Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) shares rallied 8.8% in the last trading session to close at $8.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typica...
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last?
Janux Therapeutics, Inc. (JANX) shares rallied 8.8% in the last trading session to close at $29.76. This move can be attributable to notable volume with a higher number of shares being traded than in ...
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK (GSK) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjus...
Janux Therapeutics (JANX) Shares Cross Above 200 DMA
In trading on Tuesday, shares of Janux Therapeutics Inc (Symbol: JANX) crossed above their 200 day moving average of $28.34, changing hands as high as $31.59 per share. Janux Therapeutics Inc shares ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.